An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer
David T. Miyamoto(Broad Institute), Daniel A. Haber(Howard Hughes Medical Institute), Erin Emmons(Harvard University), Douglas M. Dahl(Harvard University), David T. Ting(Massachusetts General Hospital), Erin Silva(Yale University), Xin Hong(Southern University of Science and Technology), John Milner(National Cancer Institute), Mark Kalinich(Harvard University), Ravi Kapur(Harvard University), Francis J. McGovern(Massachusetts General Hospital), Richard J. Lee(La Roche College), Katherine Broderick(Harvard University), Uyen Ho(Harvard University), Chin‐Lee Wu, Jason A. Efstathiou(Harvard University), Joseph A. LiCausi(Harvard University), Shyamala Maheswaran(Massachusetts General Hospital), Anita Giobbie‐Hurder(Institute for Tourism), Shannon L. Stott(Shriners Hospitals for Children - Erie), Lecia V. Sequist(Harvard University), Mehmet Toner(Shriners Hospitals for Children - Erie), Yu Zheng(Howard Hughes Medical Institute), Tianqi Chen(Zhejiang A & F University), Sarah Javaid(Harvard University), Matthew R. Smith(Harvard University), Tanya T. Kwan(Howard Hughes Medical Institute)
Cited by 140
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k